Literature DB >> 21134655

Altered fractionation: rationale and justification for whole and partial breast hypofractionated radiotherapy.

Valérie Théberge1, Tim Whelan, Simona F Shaitelman, Frank A Vicini.   

Abstract

Over the last 2 decades, we have seen major advances in the application of radiotherapy after breast-conserving surgery. Two important contributions are the use of whole-breast hypofractionation and accelerated partial-breast irradiation. Three large randomized trials comparing whole-breast hypofractionation versus conventional fractionation for early breast cancer have shown similar rates of local recurrence and morbidity. As a result, whole-breast hypofractionation is now an option for selected patients after breast-conserving surgery. The delivery of accelerated partial-breast irradiation (APBI) has been studied using techniques of multicatheter interstitial brachytherapy, balloon-based brachytherapy, external-beam radiotherapy, and intraoperative radiotherapy. Multiple single and multi-institutional data have been published indicating good long-term results with APBI (in highly selected, low-risk patients) in terms of tumor control and toxicity. However, the long-term results of large, phase III trials comparing APBI with whole-breast irradiation are still pending.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21134655     DOI: 10.1016/j.semradonc.2010.08.007

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  6 in total

1.  Single dose IOERT versus whole breast irradiation : Cosmetic results in breast-conserving therapy.

Authors:  Henk Struikmans; Malou Snijders; Mirjam E Mast; Ursula Fisscher; Jan-Huib Franssen; Marcelle J Immink; Andreas Marinelli; Jos Merkus; Anna Petoukhova; Gabrielle Speijer; Peter Koper
Journal:  Strahlenther Onkol       Date:  2016-08-18       Impact factor: 3.621

2.  Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.

Authors:  Charlotte E Coles; Clare L Griffin; Anna M Kirby; Jenny Titley; Rajiv K Agrawal; Abdulla Alhasso; Indrani S Bhattacharya; Adrian M Brunt; Laura Ciurlionis; Charlie Chan; Ellen M Donovan; Marie A Emson; Adrian N Harnett; Joanne S Haviland; Penelope Hopwood; Monica L Jefford; Ronald Kaggwa; Elinor J Sawyer; Isabel Syndikus; Yat M Tsang; Duncan A Wheatley; Maggie Wilcox; John R Yarnold; Judith M Bliss
Journal:  Lancet       Date:  2017-08-02       Impact factor: 79.321

3.  Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.

Authors:  R K Charaghvandi; B van Asselen; M E P Philippens; H M Verkooijen; C H van Gils; P J van Diest; R M Pijnappel; M G G Hobbelink; A J Witkamp; T van Dalen; E van der Wall; T C van Heijst; R Koelemij; M van Vulpen; H J G D van den Bongard
Journal:  BMC Cancer       Date:  2017-03-09       Impact factor: 4.430

4.  Cost Minimization Analysis of Hypofractionated Radiotherapy.

Authors:  Hannah L Yaremko; Gordon E Locke; Ronald Chow; Michael Lock; Robert Dinniwell; Brian P Yaremko
Journal:  Curr Oncol       Date:  2021-01-30       Impact factor: 3.677

5.  The Impact of Different Simulation Modalities on Target Volume Delineation in Breast-Conserving Radiotherapy.

Authors:  Meng Jin; Xia Liu; Jiabin Ma; Xiansong Sun; Hongnan Zhen; Jing Shen; Zhikai Liu; Xin Lian; Zheng Miao; Ke Hu; Xiaorong Hou; Fuquan Zhang
Journal:  Cancer Manag Res       Date:  2021-07-12       Impact factor: 3.989

6.  MRI and CT imaging for preoperative target volume delineation in breast-conserving therapy.

Authors:  Mariska D den Hartogh; Marielle E P Philippens; Iris E van Dam; Catharina E Kleynen; Robbert J H A Tersteeg; Ruud M Pijnappel; Alexis N T J Kotte; Helena M Verkooijen; Maurice A A J van den Bosch; Marco van Vulpen; Bram van Asselen; Hjg Desirée van den Bongard
Journal:  Radiat Oncol       Date:  2014-02-26       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.